Clinical trial of ShatPlus in SARS-CoV-2 Infection.

Phase 2

Completed

• Conditions: Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere

• Registration Number: CTRI/2021/06/034132
• Lead Sponsor: BVG Life Sciences Ltd BVG Group

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Completion: 2021-08-23
• Last Update Posted: 24 November 2021

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 60

Inclusion Criteria

1.Age :18- 60 years (Both sex)

2.Confirmed COVID 19 Subject with positive RT-PCR

3.Mild to moderate disease (NEWS score <7) with or without comorbidity

4.Subject willing to provide consent and follow up for study duration

Exclusion Criteria

1.Subjects with compromised immunity, autoimmune disease or self-reports HIV or syphilis infection

2.Proves to be unfit for the study as per the investigatorâ??s discretion

3.Pregnant or lactating women

4.Requiring supplemental oxygen and ICU admission at screening

5.Known case of comorbidity which is uncontrolled and which in investigator discretion finds subject not suitable for the trial participation

6.Any other medical condition like History of MI, Epileptic episodes finding subject not fit for trial participation

Study & Design

• Study Type: Interventional
• Study Design: Not specified